keyword
MENU ▼
Read by QxMD icon Read
search

Testosterone therapy

keyword
https://www.readbyqxmd.com/read/28532278/tackling-non-metastatic-castration-resistant-prostate-cancer-special-considerations-in-treatment
#1
Archana Anantharaman, Eric J Small
Prostate cancer (PCa) is currently the second most common cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is the incurable form of PCa, carrying the poorest prognosis, and can develop from non-metastatic CRPC (M0 CRPC). CRPC is defined as progression of the disease with castrate level testosterone levels, achieved with primary androgen deprivation therapy (ADT). M0 CRPC is a highly heterogeneous disease process lacking clear standard of care therapies. Areas covered: In this review, a broad literature search was undertaken to explore data available for therapeutic options and guidelines in the management of M0 CRPC...
May 23, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28531768/rosa-damascena-oil-improved-sexual-function-and-testosterone-in-male-patients-with-opium-use-disorder-under-methadone-maintenance-therapy-results-from-a-double-blind-randomized-placebo-controlled-clinical-trial
#2
Vahid Farnia, Faeze Tatari, Mostafa Alikhani, Jalal Shakeri, Moshen Taghizadeh, Hassan Karbasizadeh, Dena Sadeghi Bahmani, Edith Holsboer-Trachsler, Serge Brand
BACKGROUND: Some patients with opioid use disorder (OUD) are treated with methadone maintenance therapy (MMT). However, as with opioids, methadone has major side-effects; sexual dysfunction is a particularly distressing such effect. Rosa Damascena oil has been shown to reduce subjective sexual dysfunction in patients with major depressive disorders, but its influence on testosterone has not so far been tested. The aim of the present study was to investigate the influence of Rosa Damascena oil on sexual dysfunction and testosterone levels among male patients with OUD and undergoing MMT...
April 6, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/28526632/erythrocytosis-following-testosterone-therapy
#3
REVIEW
Samuel J Ohlander, Bibin Varghese, Alexander W Pastuszak
INTRODUCTION: A rapid increase in awareness of androgen deficiency has led to substantial increases in prescribing of testosterone therapy (TTh), with benefits of improvements in mood, libido, bone density, muscle mass, body composition, energy, and cognition. However, TTh can be limited by its side effects, particularly erythrocytosis. This review examines the literature on testosterone-induced erythrocytosis and polycythemia. AIM: To review the available literature on testosterone-induced erythrocytosis, discuss possible mechanisms for pathophysiology, determine the significance of formulation, and elucidate potential thromboembolic risk...
May 16, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28522646/mr-spectroscopy-of-hepatic-fat-and-adiponectin-and-leptin-levels-during-testosterone-therapy-in-type-2-diabetes-a-randomized-double-blinded-placebo-controlled-trial
#4
Line Velling Magnussen, Poul Erik Andersen, Anabel Diaz, Jelena Markovic Ostojic, Kurt Højlund, David M Hougaard, Anders Nymark Christensen, Torben Leo Nielsen, Marianne Skovsager Andersen
BACKGROUND: Men with type 2 diabetes mellitus (T2D) often have lowered testosterone levels and an increased risk of cardiovascular disease (CVD). Ectopic fat increases the risk of CVD, whereas subcutaneous gluteofemoral fat protects against CVD and has a beneficial adipokine secreting profile. HYPOTHESIS: Testosterone replacement therapy (TRT) may reduce the content of ectopic fat and improve the adipokine profile in men with T2D. DESIGN AND METHODS: A randomized, double-blinded, placebo-controlled study in 39 men aged 50-70 years with T2D and bioavailable testosterone levels <7...
May 18, 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28511045/stigma-and-diurnal-cortisol-among-transitioning-transgender-men
#5
L Zachary DuBois, Sally Powers, Bethany G Everett, Robert-Paul Juster
This study assessed diurnal cortisol functioning in relation to stigma-based transition-specific stressors experienced by transgender men during their transition from female to male. Sixty-five healthy transgender men undergoing testosterone therapy participated in in-person interviews through which transition-specific stressors were identified. Interviews were coded according to participant reported (1) Transitioning-identity stress; (2) Coming Out stress; (3) Gender-specific Public Bathroom stress; and (4) levels of general Perceived Stress...
May 8, 2017: Psychoneuroendocrinology
https://www.readbyqxmd.com/read/28509626/custom-compounded-bioidentical-hormone-therapy-why-so-popular-despite-potential-harm-the-case-against-routine-use
#6
M L'Hermite
Wide rejection of conventional hormone therapy (HT) after the initial publication of the Women's Health Initiative (WHI) led to unjustified use of custom-compounded bioidentical hormones. In the USA, it became an unregulated drug manufacturer industry in disguise, without proper control and making false claims and misleading advertisements. Manufacturing quality is not ensured. Unspecific harm from compounding has occurred on a large scale, such as deaths from infected products and end-stage renal failure plus carcinoma due to confusion between different Chinese herbs...
June 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28508601/effects-of-anorexia-nervosa-on-the-endocrine-system
#7
Charumathi Baskaran, Madhusmita Misra, Anne Klibanski
Anorexia nervosa (AN) is characterized by severe undernutrition associated with alterations in multiple endocrine axes, which are primarily adaptive to the state of caloric deprivation. Hormonal changes include growth hormone (GH) resistance with low insulin like growth factor-1 (IGF-1) levels, hypothalamic hypogonadism, relative hypercortisolemia and changes in appetite regulating hormones, including leptin, ghrelin, and peptide YY. These alterations contribute to abnormalities in bone metabolism leading to low bone mass, impaired bone microarchitecture, and increased risk for fracture, and may also negatively impact cognition, emotions and mood...
March 2017: Pediatric Endocrinology Reviews: PER
https://www.readbyqxmd.com/read/28497912/testosterone-replacement-therapy-long-term-safety-and-efficacy
#8
REVIEW
Giovanni Corona, Alessandra Sforza, Mario Maggi
Recent position statements and guidelines have raised the distinction between a true and false, age-related hypogonadism (HG) or late-onset hypogonadism (LOH). The former is the consequence of congenital or acquired "organic" damage of the brain centers or of the testis. The latter is mainly secondary to age-related comorbidities and does not require testosterone (T) therapy (TTh). In addition, concerns related to cardiovascular (CV) safety have further increased the scepticism related to TTh. In this paper, we reviewed the available evidence supporting the efficacy of TTh in non-organic HG and its long term safety...
April 30, 2017: World Journal of Men's Health
https://www.readbyqxmd.com/read/28497534/effects-of-testosterone-replacement-therapy-on-metabolic-syndrome-among-japanese-hypogonadal-men-a-subanalysis-of-a-prospective-randomised-controlled-trial-earth-study
#9
K Shigehara, H Konaka, T Nohara, K Izumi, Y Kitagawa, Y Kadono, T Iwamoto, E Koh, A Mizokami, M Namiki
We investigated the effects of testosterone replacement therapy (TRT) on metabolic factors among hypogonadal men with a metabolic syndrome. From the study population of the EARTH study, which was a randomised controlled study in Japan, 65 hypogonadal patients with a metabolic syndrome, comprising the TRT group (n = 32) and controls (n = 33), were included in this study analysis. The TRT group was administered 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 12 months...
May 12, 2017: Andrologia
https://www.readbyqxmd.com/read/28495834/testosterone-therapy-for-menopausal-women
#10
(no author information available yet)
It has been suggested that there is a link between low circulating concentrations of testosterone and reduced sexual functioning in postmenopausal women,(1) and it has been more than 60 years since the effects of testosterone therapy for the management of menopausal symptoms were first reported.(2) Since then, testosterone supplementation has received growing attention for its potential role in maintaining sexual function in menopausal women. The National Institute for Health and Care Excellence guideline on the diagnosis and management of menopause recommends considering testosterone supplementation for women with low sexual desire if hormone replacement therapy (HRT) alone has been ineffective...
May 2017: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/28490267/darolutamide-odm-201-for-the-treatment-of-prostate-cancer
#11
Neal D Shore
Androgen deprivation therapy (ADT) is a mainstay initial treatment for advanced hormone-sensitive prostate cancer (HSPC), but disease progression to castration-resistant prostate cancer (CRPC) invariably occurs when patients do not succumb to another disease or comorbidity. Recognition that the androgen receptor (AR) axis continues to drive disease progression has led to the development of several AR-directed approved agents, including abiraterone acetate and enzalutamide. An investigational agent, darolutamide (ODM-201, BAY-1841788), has completed early-phase clinical trials, and two global phase III trials are currently accruing patients...
May 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28487389/normalization-of-testosterone-levels-after-testosterone-replacement-therapy-is-associated-with-decreased-incidence-of-atrial-fibrillation
#12
Rishi Sharma, Olurinde A Oni, Kamal Gupta, Mukut Sharma, Ram Sharma, Vikas Singh, Deepak Parashara, Surineni Kamalakar, Buddhadeb Dawn, Guoqing Chen, John A Ambrose, Rajat S Barua
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac dysrhythmia associated with significant morbidity and mortality. Several small studies have reported that low serum total testosterone (TT) levels were associated with a higher incidence of AF. In contrast, it is also reported that anabolic steroid use is associated with an increase in the risk of AF. To date, no study has explored the effect of testosterone normalization on new incidence of AF after testosterone replacement therapy (TRT) in patients with low testosterone...
May 9, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28487215/micturition-dysfunction-in-four-month-old-ovariectomized-rats-effects-of-testosterone-replacement
#13
Sandra M Bonilla-Becerra, Mariana G de Oliveira, Fabiano B Calmasini, Julio A Rojas-Moscoso, Angelina Zanesco, Edson Antunes
AIMS: Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats. MAIN METHODS: Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated...
May 6, 2017: Life Sciences
https://www.readbyqxmd.com/read/28485412/science-and-society-testosterone-replacement-therapy-and-the-knowledge-gap
#14
Yooni A Yi, James M Dupree
No abstract text is available yet for this article.
May 9, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28482050/parallel-assessment-of-the-effects-of-bisphenol-a-and-several-of-its-analogs-on-the-adult-human-testis
#15
C Desdoits-Lethimonier, L Lesné, P Gaudriault, D Zalko, J P Antignac, Y Deceuninck, C Platel, N Dejucq-Rainsford, S Mazaud-Guittot, B Jégou
STUDY QUESTION: Are bisphenol A (BPA) and BPA analogs (BPA-A) safe for male human reproductive function? SUMMARY ANSWER: The endocrine function of human testes explants [assessed by measuring testosterone and insulin-like factor 3 (INSL3)] was impacted by exposure of the human adult testis explants to BPA/BPA-A. WHAT IS KNOWN ALREADY: The few epidemiologic studies performed suggest that bisphenols have potential endocrine disruptive properties, but they did not identify clear and direct patterns of endocrine disruption...
May 8, 2017: Human Reproduction
https://www.readbyqxmd.com/read/28480768/degarelix-versus-luteinizing-hormone-releasing-hormone-agonists-for-the-treatment-of-prostate-cancer
#16
Timothy N Clinton, Solomon L Woldu, Ganesh V Raj
Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28479477/practice-patterns-in-the-diagnosis-and-management-of-hypogonadism-a-survey-of-smsna-members
#17
Faysal A Yafi, Nora M Haney, James Anaissie, Kenneth J DeLay, Landon Trost, Mohit Khera, Wayne J G Hellstrom
OBJECTIVE: To describe practice patterns in the diagnosis and treatment of hypogonadism, as the optimal approaches are controversial. Multiple therapeutic options are currently available for hypogonadal men and treatment patterns vary considerably. The safety of testosterone therapy (TTh) remains understudied. METHODS: A 23-question survey regarding diagnosis and treatment of hypogonadism was sent to all members of the Sexual Medicine Society of North America (SMSNA)...
May 4, 2017: Urology
https://www.readbyqxmd.com/read/28472914/low-testosterone-levels-and-metabolic-syndrome-in-aging-male
#18
Rodrigo Blaya, Patrícia Blaya, Luiza Rhoden, Ernani Luis Rhoden
Advances in medicine and progressive improvements in the health of the general population in developed countries have led to considerable increases in life expectancy over recent years. Metabolic syndrome (MetS) affects approximately 25% of the adult population and its prevalence is increasing all over the world. Central obesity plays an important role in emergence of MetS. Some studies have suggested that there may be link between low Total Testosterone levels and emergence of MetS. The objective of this review is to analyze the complex network of interactions between MetS and low testosterone levels in elderly men, considering etiologic, diagnostic, and therapeutic aspects...
May 3, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28472487/11-oxygenated-androgens-are-biomarkers-of-adrenal-volume-and-testicular-adrenal-rest-tumors-in-21-hydroxylase-deficiency
#19
Adina F Turcu, Ashwini Mallappa, Meredith Elman, Nilo A Avila, Jamie Marko, Hamsini Rao, Alexander Tsodikov, Richard J Auchus, Deborah P Merke
Context: Patients with 21-hydroxylase deficiency (21OHD) suffer from long-term complications, which might result from poor disease control and/or glucocorticoid overtreatment. Lack of optimal biomarkers has made it challenging to tailor therapy and to predict long-term outcomes. Objective: To identify biomarkers of disease control and long-term complications in 21OHD. Setting and participants: Cross-sectional study of 114 patients (70 males), ages 2 to 67 (median, 15) years, seen in a tertiary referral center...
May 1, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28472278/dihydrotestosterone-biochemistry-physiology-and-clinical-implications-of-elevated-blood-levels
#20
Ronald S Swerdloff, Robert E Dudley, Stephanie T Page, Christina Wang, Wael A Salameh
This review on dihydrotestosterone (DHT) biochemistry, physiology, and clinical implications of elevated levels in blood clarifies concepts that are important in clinical practice. Benefits associated with lowered serum DHT levels after 5α-reductase inhibitor (5AR-I) therapy in men have contributed to a misconception that circulating DHT levels are an important stimulus for androgenic action in target tissues (e.g., prostate). Yet evidence from clinical studies indicate that intracellular concentrations of androgens (particularly in androgen-sensitive tissues) are essentially independent of circulating levels...
May 2, 2017: Endocrine Reviews
keyword
keyword
7858
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"